Tag Archives: VBP

Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.

Posted on December 4, 2013 by Barbara Arzymanow

The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading →

Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban | Tagged , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.

Posted on September 20, 2012 by Barbara Arzymanow

David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading →

Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Branded vs. generic debate continues

Posted on May 7, 2010 by emma2020

The debate around cutting costs had taken a view that by swapping branded drugs for generics will somehow help the NHS make £20 billion of savings, is disproportionate and ill informed. In a really interesting survey carried out by the … Continue reading →

Posted in competition, Drugs | Tagged | Leave a comment